VTVT > Dew, Peter and the board in general... I would love to hear your thoughts on this phase III AD trial for TP-488/Azeliragon which targets RAGE (Receptor for Advanced Glycation End-Products).
There are no other RAGE drugs under development in AD at present however there is some rationale for the target...
(2017) Ligands of Receptor for Advanced Glycation End-Products Produced by Activated Microglia are Critical in Neurodegenerative Diseases https://goo.gl/3JAtvc
(2012) The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310161/
TP-488 was discovered by Transtech Pharma and licensed to Pfizer. A phase 2b clinical trial was stopped due to the worsening of patients in the high dosage arm. The drug was returned to Transtech which morphed into VTVT. The CEO of Pfizer at the time was Jeffrey Kindler who was ousted in a reported boardroom coup...Kindler is now Chairman of the BOD of VTVT.
VTVT is claiming the trial was stopped prematurely and the futility analysis is suspect...
Disclosure: I have a very tiny position in VTVT...I’m on the fence leaning towards dumping it and looking for any reasons to do so - lol.
They were supposed to report "initial data for the first group, in early 2017" which is nowhere to be found..that's probably reason enough to eject my small stake right there.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.